Menopausal Hot Flashes Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F Segmented by Type (Oral Liquid v/s Pill), By Treatment Type (Hormonal Treatment, Non-Hormonal Treatment, Alternative Treatment), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), By Region and Competition
Published Date: November - 2024 | Publisher: MIR | No of Pages: 320 | Industry: Healthcare | Format: Report available in PDF / Excel Format
View Details Buy Now 2890 Download Sample Ask for Discount Request CustomizationMenopausal Hot Flashes Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F Segmented by Type (Oral Liquid v/s Pill), By Treatment Type (Hormonal Treatment, Non-Hormonal Treatment, Alternative Treatment), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), By Region and Competition
According to the study "Frequent hot flashes in women, 40 to 65 years of age with metabolic syndrome" published in December 2020, women over the age of 40 are more likely to have a fever, about 55.83%, and appear to be associated with metabolic syndrome.
Growing Incidences of Menopausal Hot Flashes
Growing Innovation in Medicine
Market Segmentation
Global Menopausal Hot Flashes Treatment market can be segmented on the basis of type, treatment type, distribution channel, and by region. Based on type, the market can be further bifurcated into oral liquid and pill. Based on treatment type, the market can be further divided into hormonal treatment, non-hormonal treatment, and alternative treatment. Based on distribution channels, the market is further split into hospital pharmacies, retail pharmacies, and online pharmacies. On the basis of region, North America dominated the market among Asia Pacific, Europe, Middle East & Africa, and South America. On the basis of countries, the United States dominated the global Menopausal Hot Flashes Treatment market on account of the increasing number of women reaching menopausal age.
Recent Development
- The U.S. Food and Drug Administrationreceived a new drug application (NDA) for fezolinetant from Astellas PharmaInc. in June 2022. (FDA). For the treatment of mild to severe vasomotorsymptoms (VMS) related to menopause, the experimental oral, nonhormonalchemical fezolinetant is awaiting for approval.
- In February 2021, Astellas Pharma Inc.announced the positive results from the Phase 3 pivotal SKYLIGHT 1 and SKYLIGHT2 clinical trials or fezolinetant, which is an oral, non-hormonal compoundbeing tested for the treatment of moderate to severe vasomotor symptoms (VMS).
- In January 2020, Bayer AG strengthened itsdrug discovery platform through acquisition of Vividion Therapeutics. VividionTherapeutics produces a variety of small molecule therapies across indicationsand their initial focus was on targets relevant to oncology and immunology.
Market Players
Abbvie, Inc., Allergan PLC., Bayer AG., Cipla, Inc., Eli Lilly and Company, Emcure Pharmaceuticals Ltd., GSK PLC., Glenmark Pharmaceuticals Ltd., Hisamitsu Pharmaceutical Co. Inc., Merck & Co. Inc. , Novartis Ag., Novo Nordisk AS., Pfizer, Inc., Teva Pharmaceutical Industries Ltd., and TherapeuticsMD, Inc. are some of the leading players operating in the Global Menopausal Hot Flashes Treatment Market.
| Attribute | Details |
| Base Year | 2022 |
| Historic Data | 2018 – 2021 |
| Estimated Year | 2023 |
| Forecast Period | 2024 – 2028 |
| Quantitative Units | Revenue in USD Million, and CAGR for 2018-2022 and 2023-2028 |
| Report Coverage | Revenue forecast, company share, competitive landscape, growth factors, and trends |
| Segments Covered | By Type By Treatment Type By Distribution Channel By Region |
| Regional scope | North America, Europe, Asia Pacific, South America, Middle East & Africa |
| Country scope | United States, Canada, Mexico, France, Germany, United Kingdom, Italy, Spain, China, India, Japan, South Korea, Australia, Brazil, Argentina, Colombia, South Africa, Saudi Arabia, UAE |
| Key companies profiled | Abbvie, Inc., Allergan PLC., Bayer Ag., Cipla, Inc., Eli Lilly and Company, Emcure Pharmaceuticals Ltd., GSK PLC., Glenmark Pharmaceuticals Ltd., Hisamitsu Pharmaceutical Co. Inc., Merck & Co. Inc. , Novartis Ag., Novo Nordisk AS., Pfizer, Inc., Teva Pharmaceutical Industries Ltd., TherapeuticsMD, Inc. |
| Customization scope | 10% free report customization with purchase. Addition or alteration to country, regional & segment scope. |
| Pricing and purchase options | Avail customized purchase options to meet your exact research needs. Explore purchase options |
| Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
FAQ'S
For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:
Within 24 to 48 hrs.
You can contact Sales team (sales@marketinsightsresearch.com) and they will direct you on email
You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.
Discounts are available.
Hard Copy